Capivasertib (Truqap)

Overview

Capivasertib has been investigated for the treatment of Metastatic Breast Cancer.

Indications

Capivasertib (Truqap) is indicated in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN alterations, as detected by an FDA-approved test, following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.

• Metastatic Breast Cancer
• Hormone Receptor-Positive Breast Cancer
• HER2-Negative Breast Cancer